CV vs REGN · rev $3.5M vs P/E 14, rev $14.34B
CapsoVision, Inc. Common Stock (CV) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
CapsoVision, Inc. Common Stock (CV) is a medical devices company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CV revenue for 2025-09-30 was $3.5M. Net income was -$7.9M. Revenue was up 6.7% from 2025-06-30 to 2025-09-30. CV currently screens at market cap $359.2M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CV currently screens at market cap $359.2M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CV and REGN stock pages for the full models.
Not investment advice.